XPeng Inc.
XPEVConsumer CyclicalNASDAQAuto Manufacturers
Scan Results
Daily timeframeHeadquartered within the consumer cyclical sector, XPeng Inc. focuses on Auto Manufacturers services and products. XPeng Inc. operates as a physical AI company. The company carries a $8.82B market cap, placing it firmly in the mid-cap category. It has developed a Physical AI architecture covering Turing AI chips, foundation models, and integrated software and hardware applications.
Market Cap
$8.82B
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
49.80
EPS (TTM)
$-0.45
EPS (Fwd)
$0.18
ROE
-10.9%
ROA
-2.4%
Cash
$28.04B
Total Debt
$26.86B
Free CF
—
52W Change
-60.0%
Annual Financials
Cash vs Debt
Where XPEV stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, XPEV finished 31.49% below its 150-day moving average ($14.10) and 36.66% below its 200-day moving average ($15.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XPEV overbought or oversold?
At the October 13, 2026 close, XPEV's RSI(14) was 32.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $28.04B in cash comfortably exceeding the $26.86B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. ROE of -10.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $26.86B (2022) to $76.72B (2025), reflecting a 186% increase over the period.
As with any equity investment, XPEV carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XPEV.